Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Taking Vemlidy rather than Viread as prophylaxis against hepatitis B is tied to better markers of kidney and bone health.
Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.
Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.
A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.
The exception is those people with hepatitis B and liver cancer.
Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.
Such generic drugs could save nations huge sums in the coming years.
Treatment with Viread and Baraclude led to a decline in liver cancer in Europe but not in South Korea.
Regardless of whether individuals have hepatitis B or C, the improvement tends to occur quickly.
The experimental drug is apparently safer to bones and kidneys.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.